Drug Profile
MLN 8054
Alternative Names: MLN8054Latest Information Update: 11 Nov 2008
Price :
$50
*
At a glance
- Originator Millennium Pharmaceuticals
- Developer Millennium
- Class Antineoplastics; Small molecules
- Mechanism of Action Aurora kinase A inhibitors; Mitosis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Liver cancer; Solid tumours
Most Recent Events
- 14 May 2008 Millennium Pharmaceuticals has been acquired by Takeda
- 12 Jun 2007 Data presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2007) added to the adverse events and Cancer therapeutic trials sections
- 01 Dec 2006 Data presented at the 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2006) added to the adverse events and Cancer pharmacodynamics sections